ScoreWhy is BioXcel Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
11.84%
EBIT Growth (5y)
5.18%
EBIT to Interest (avg)
-44.22
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.83
Sales to Capital Employed (avg)
0.14
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.62%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.42
EV to EBIT
-2.21
EV to EBITDA
-2.22
EV to Capital Employed
-6.46
EV to Sales
109.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -58.22 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 501.33 times
RAW MATERIAL COST(Y)
Fallen by -102.32% (YoY
NET PROFIT(9M)
Higher at USD -46.99 MM
-19What is not working for the Company
NET SALES(HY)
At USD 0.22 MM has Grown at -83.46%
PRE-TAX PROFIT(Q)
At USD -19.04 MM has Fallen at -51.06%
NET PROFIT(Q)
At USD -19.04 MM has Fallen at -51.06%
CASH AND EQV(HY)
Lowest at USD 55.89 MM
Here's what is working for BioXcel Therapeutics, Inc.
Operating Cash Flow
Highest at USD -58.22 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Debtors Turnover Ratio
Highest at 501.33 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -102.32% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for BioXcel Therapeutics, Inc.
Net Sales
At USD 0.22 MM has Grown at -83.46%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -19.04 MM has Fallen at -51.06%
over average net sales of the previous four periods of USD -12.6 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -19.04 MM has Fallen at -51.06%
over average net sales of the previous four periods of USD -12.6 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 55.89 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
